Navigating The Complex Route To Regulatory Compliance, From Preclinical To Market

By Josh Hoerner, General Manager Siegfried Acceleration Hub Athens, US

Bringing a drug candidate from preclinical development to commercialization requires more than scientific innovation. Success depends on navigating a complex and evolving regulatory landscape while making development decisions that support long-term compliance from the outset. Regulatory expectations vary across regions, and missteps made early in development can lead to costly delays, rework, and increased risk later in the program.

A proactive regulatory strategy helps ensure alignment with agency requirements, including Chemistry, Manufacturing and Controls (CMC) expectations, quality standards, and documentation requirements. Early planning also enables developers to anticipate emerging regulatory priorities, address potential manufacturing and impurity concerns, and streamline the path through clinical development and approval.

From IND preparation and regional regulatory submissions to post-approval obligations, regulatory considerations influence every stage of a product’s lifecycle. Understanding these requirements early can help organizations accelerate development timelines, reduce compliance risks, and position promising therapies for successful global commercialization.